Key Highlights

  • Pre-market trading on November 3, 2026 pushed shares down 11.68% to USD 4.99.
  • Nothing dated November 2 or November 3, 2026 from the company was located.
  • On October 8, 2026, Nasdaq staff decided to delist the stock for failing the USD 2.5 million Equity rule.
  • As of October 30, 2026, the Cortigent Merger had not received final regulatory approval.
  • Excluding the financing, Vivani would hold about 77.98% of the combined company.

What Pushed ClearOne Shares Lower Before the Open (down USD 0.6599, 11.68%)

ClearOne (NASDAQ:CLRO) dropped 11.68% to USD 4.99 in pre-market dealings on November 3, 2026. Counting back from Monday, November 2, 2026, the implied prior close is roughly USD 5.65 (calculated).

No company announcement dated November 2 or November 3, 2026 was located. The slide comes after a run of extreme swings, and one market commentary put trading at about 83.1 million shares on October 26, 2026 against a public float of around 714,000.

The Cortigent Merger and Financing

Under a deal announced July 2, 2026, Cortigent, Inc., a unit of Vivani Medical (NASDAQ:VANI), would turn into a wholly owned ClearOne subsidiary. On October 30, 2026, Vivani stated that closing was still awaiting final regulatory approval, after earlier expecting an October completion.

A regulatory filing indicates Vivani would control about 77.98% of the merged company, while current ClearOne holders would hold about 16.69%. Completion depends on a financing of USD 10.0 million to USD 15.0 million issued in units of one share and one warrant, which adds fresh dilution to the structure.

Business History and Recent Figures

ClearOne previously produced audio conferencing and collaboration products. It divested those Assets to Biamp Systems for USD 3.0 million gross, closing on October 24, 2025, and stated it would stay a public company. Cortigent is a pre-revenue neurostimulation Business whose Orion cortical visual prosthesis remains investigational.

Market data for the June 2026 quarter shows a net loss of about USD 914,000 and cash of about USD 75,000. The auditors voiced substantial doubt about the company's ability to keep operating as a going concern.

Listing and Balance Sheet Concerns

On October 8, 2026, Nasdaq staff concluded the shares should be Delisted because ClearOne fell short of the USD 2.5 million stockholders' equity requirement and did not complete its May 22, 2026 compliance plan. The company planned to request a hearing by October 15, 2026, a step that holds off any suspension while a panel reviews a new plan.

Its majority holder extended a Loan of up to USD 1 million, due December 30, 2026. With the stock under USD 5 and about 2.68 million shares outstanding, this Penny Stock faces heavy volatility, Liquidity and dilution risk.

Next Markers to Track

Key signals include any news of regulatory clearance, the pricing of the financing, the outcome of the Nasdaq hearing and any reverse split ratio. The merger filing points to an outside date near late December 2026 (calculated from the filing terms).

Absent new disclosure, the stock may keep trading mainly on the small float rather than company news.